

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 June 2025 (05.06.2025)



(10) International Publication Number
WO 2025/114875 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 487/04 (2006.01)
C07D 413/14 (2006.01) C07D 491/10 (2006.01)
C07D 417/14 (2006.01) A61P 35/00 (2006.01)
C07D 471/04 (2006.01) A61K 31/4412 (2006.01)

(21) International Application Number:

PCT/IB2024/061842

(22) International Filing Date:

26 November 2024 (26.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/604,926 01 December 2023 (01.12.2023) US
63/650,019 21 May 2024 (21.05.2024) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151-85, Södertälje (SE).

(72) Inventors: **ANDERSON, Niall**; c/o AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **DÄMGEN, Marc André**; c/o AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **EVANS, Laura**; c/o AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **FALLAN, Charlene**; c/o AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **GOLDBERG, Frederick**; c/o ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2-0AA (GB). **HAYHOW, Thomas George Christopher**; c/o ASTRAZENECA UK


LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB). **NISSINK, Johannes Wilhelmus Maria**; c/o AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **PACKER, Martin John**; c/o AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **SCOTT, James**; c/o AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **STEWART, Oliver**; c/o AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB).

(74) Agent: **WALTON, Laura**; ASTRAZENECA INTELLECTUAL PROPERTY, Eastbrook House, Shaftesbury Road, Cambridge Cambridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: ER DEGRADERS AND USES THEREOF



(I)

(57) Abstract: This specification relates to compounds according to Formula (I), which are of degraders of ER, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of ER-sensitive and/or ER-directed diseases and disorders.

[Continued on next page]

WO 2025/114875 A1

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*